4-[2-(2,4-dichloro-phenoxy)-4-methoxy-phenylsulfamoyl]-N-{[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide hydrochloride | 1021522-51-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[2-(2,4-dichloro-phenoxy)-4-methoxy-phenylsulfamoyl]-N-{[(piperidin-4-ylmethyl)-carbamoyl]-methyl}-benzamide hydrochloride
• 英文别名: 4-[[2-(2,4-dichlorophenoxy)-4-methoxyphenyl]sulfamoyl]-N-[2-oxo-2-(piperidin-4-ylmethylamino)ethyl]benzamide;hydrochloride
• CAS: 1021522-51-9
• 化学式: C₂₈H₃₀Cl₂N₄O₆S*ClH
• 分子量: 658.002
• InChiKey: NCJGUZPWSRVRIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.86
• 重原子数：
  42
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  143
• 氢给体数：
  5
• 氢受体数：
  8

文献信息

• [EN] HEPATITIS C INHIBITOR DIPEPTIDE ANALOGS<br/>[FR] ANALOGUES DIPEPTIDIQUES D'INHIBITEURS DE L'HEPATITE C
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2006007700A1

  公开（公告）日：2006-01-26

  The present invention relates to compounds of formula (I): wherein R1, R2, R4, n and m are as defined herein and R3 is selected from: (i) -C(O)OR31 wherein R31 is (C1-6)alkyl or aryl, wherein the (C1-6)alkyl is optionally substituted with one to three halogen substituents; (ii) -C(O)NR32R33, wherein R32 and R33 are each independently selected form H, (C1-6)alkyl, and Het; (iii) -SOvR34, wherein v is 1 or 2 and R34 is selected from: (C1-6)alkyl, aryl, Het, and NR32R33 wherein R32 and R33 are as defined above; and (iv) -CO(O)-R35, wherein R35 is selected from (C1-8)alkyl, (C3-7)cycloalkyl-(C1-4)alkyl, aryl, aryl-(C1-6)alkyl, Het and Het-(C1-6)alkyl, each of which are optionally substituted with one or more substituents each independently selected from halo, (C1-6)alkyl, (C3-7)cycloalkyl, aryl, Het, hydroxyl, -O-(C1-6)alkyl, -S-(C1-6)alkyl, -SO-(C1-6)alkyl, -SO2-(C1-6)alkyl, -O-aryl, -S-aryl, -SO-aryl and -SO2-aryl, wherein the aryl portion of the -O-aryl, -S-aryl, -SO-aryl and -SO2-aryl are each optionally substituted with one to five halo substituents. The present invention further relates to pharmaceutical compositions containing the compounds of formula (I) and methods for using these analogs in the treatment of HCV infection.

  本发明涉及以下式(I)的化合物：其中R1、R2、R4、n和m如本文所定义，R3选自：(i)-C(O)OR31，其中R31为(C1-6)烷基或芳基，其中(C1-6)烷基可选择地用一到三个卤素取代基取代；(ii)-C(O)NR32R33，其中R32和R33各自独立地选自H、(C1-6)烷基和Het；(iii)-SOvR34，其中v为1或2，R34选自：(C1-6)烷基、芳基、Het和NR32R33，其中R32和R33如上所定义；和(iv)-CO(O)-R35，其中R35选自(C1-8)烷基、(C3-7)环烷基-(C1-4)烷基、芳基、芳基-(C1-6)烷基、Het和Het-(C1-6)烷基，每种均可选择地用一种或多种取代基取代，每种取代基各自独立地选自卤素、(C1-6)烷基、(C3-7)环烷基、芳基、Het、羟基、-O-(C1-6)烷基、-S-(C1-6)烷基、-SO-(C1-6)烷基、-SO2-(C1-6)烷基、-O-芳基、-S-芳基、-SO-芳基和-SO2-芳基，其中-O-芳基、-S-芳基、-SO-芳基和-SO2-芳基的芳基部分可选择地用一到五个卤素取代基取代。本发明还涉及含有式(I)化合物的药物组合物以及在治疗HCV感染中使用这些类似物的方法。
• Hepatitis C inhibitor dipeptide analogs
  申请人：Bailey D. Murray

  公开号：US20060046965A1

  公开（公告）日：2006-03-02

  Compounds of formula (I): wherein R 1 , R 2 , R 3 , R 4 , n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.

  式(I)的化合物：其中R1、R2、R3、R4、n和m的定义如本文所述。这些化合物可用作HCV NS3蛋白酶的抑制剂。
• PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS
  申请人：Beke Gyula

  公开号：US20100105686A1

  公开（公告）日：2010-04-29

  The present invention relates to new sulfonamide derivatives of formula (I) wherein R 1 -R 8 and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selective antagonists of bradykinin B1, to processes for producing these same compounds, pharmacological compositions containing them and to their use in therapy or prevention of painful and inflammatory conditions.

  本发明涉及式(I)的新磺酰胺衍生物，其中R1-R8和Z如权利要求中所定义，以及其光学对映体或外消旋体和/或盐和/或水合物和/或溶剂化物，它们是布雷地酮B1的选择性拮抗剂，用于制备这些化合物的方法、包含它们的药理学组合物以及它们在治疗或预防疼痛和炎症状况中的应用。
• New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists
  申请人：Beke Gyula

  公开号：US20120295910A1

  公开（公告）日：2012-11-22

  The present invention relates to new sulfonamide derivatives of formula (I), wherein R 1 -R 8 and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selective antagonists of bradykinin B1, to processes for producing these same compounds, pharmacological compositions containing them and to their use in therapy or prevention of painful and inflammatory conditions.

  本发明涉及公式(I)的新磺酰胺衍生物，其中R1-R8和Z如权利要求所定义，以及其光学对映体或混合物和/或盐和/或水合物和/或溶剂化物，它们是缓激肽B1选择性拮抗剂，制备这些化合物的过程，包含它们的药理学组合物以及它们在治疗或预防疼痛和炎症疾病方面的用途。
• Hepatitis C Inhibitor Dipeptide Analogs
  申请人：BAILEY Murray D.

  公开号：US20090156822A1

  公开（公告）日：2009-06-18

  Compounds of formula (I): wherein R 1 , R 2 , R 3 , R 4 , n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.

  式(I)的化合物：其中R1、R2、R3、R4、n和m的定义如本文所述。该化合物可用作HCV NS3蛋白酶的抑制剂。